AzTrials
AzTrials

Diffuse Large B Cell LymphomaPhase 1/2NCT04572763

Copanlisib Plus Venetoclax in R/R DLBCL

A Phase 1/2 study testing Copanlisib and Venetoclax in people with Diffuse Large B Cell Lymphoma and Relapsed Diffuse Large B-Cell Lymphoma, run by Dana-Farber Cancer Institute at 3 sites in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This research study is evaluating the combination of two drugs, copanlisib and venetoclax, as a possible treatment for trelapsed/refractory diffuse large B-cell lymphoma (DLBCL) The names of the study drugs involved in this study are: Copanlisib Venetoclax Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Copanlisib and Venetoclax
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
3 sitesUnited States
Study dates
8 Sep 2021to 29 Jul 2026
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • A confirmed diagnosis of DLBCL according to the 2016 WHO classification. Patients with high-grade B-cell lymphoma with translocations of MYC and BCL-2 and/or BCL-6 are eligible
  • Relapsed after autologous stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy or not a candidate for these therapies
  • Willingness to undergo a pre-treatment biopsy. If considered unsafe to proceed with biopsy, archival tissue samples may be utilized after discussion with the PI. Archival samples performed within 90 days and without intervening therapy are also acceptable if they meet the criteria as specified in the laboratory manual.
  • ECOG performance status < 2
  • Age ≥ 18 years
  • Patients must meet the following hematologic criteria at screening:
Show all 15Show fewer
  • Absolute neutrophil count ≥1000 cells/mm3 (0.5 x 109/L), with no white-blood cell growth factor use for at least 7 days prior to screening.
  • Platelet count ≥75,000 cells/mm3 (75 x 109/L) or ≥50,000 cells/mm3 (50 x 109/L if documented disease involvement of the bone marrow), without platelet transfusion within 7 days of screening
  • Hemoglobin (Hb) ≥ 8 g/dL, without blood transfusion within 7 days of screening
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement by lymphoma)
  • Lipase ≤ 1.5 x ULN
  • Total bilirubin ≤ 1.5 x ULN (< 3 x ULN for patients with Gilbert's syndrome, patients with cholestasis due to compressive adenopathies of the hepatic hilum or documented liver involvement or with biliary obstruction due to lymphoma)
  • Adequate renal function defined by serum creatinine ≤1.5 x ULN or creatinine clearance (by Cockroft-Gault) ≥ 50 ml/min
  • Women of childbearing potential (WOCBP) and men must agree to use effective contraception when sexually active. This applies for the time period between signing of the informed consent form and 6 months for WOCBP and for men after the last administration of study treatment. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control, e.g. intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, use of two forms of birth control, and sexual abstinence. The use of condoms by male patients is required unless the female partner is permanently sterile.
  • Ability to understand and the willingness to sign a written informed consent document

Who cannot join

  • Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) within 2 weeks of Cycle 1/Day 1 with the following exceptions:
  • Limited palliative radiation is allowed if completed > 1 week of C1D1
  • Systemic corticosteroid therapy at a daily dose higher than 15 mg prednisone is allowed until C1D1.
  • Chronic systemic corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent.
  • History of other malignancies, except:
  • Malignancy treated medically or surgically with curative intent and with no known active disease present for ≥2 years before the first dose of study drug
Show all 36Show fewer
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  • Adequately treated carcinoma in situ without evidence of disease.
  • Localized prostate cancer and low-risk prostate cancer on active surveillance
  • Within three months of autologous stem cell transplantation at time of starting study treatment
  • Within six months of allogeneic stem cell transplantation at time of starting study treatment or active graft vs. host disease requiring systemic treatment or prophylaxis within 6 weeks of starting study treatment
  • Vaccinated with live, attenuated vaccines of any kind <4 weeks before first dose of study drug
  • History of or active autoimmune disease requiring systemic immunosuppression
  • Recent infection requiring intravenous antibiotics that was completed ≤7 days before the first dose of study drug, or any uncontrolled active systemic infection
  • Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications
  • Known bleeding disorders (eg, von Willebrand's disease) or hemophilia
  • History of stroke or intracranial hemorrhage within 3 months prior to enrollment
  • Known history of Human Immunodeficiency Virus (HIV) infection. All patients must be screened for HIV up to 28 days prior to study drug start using a blood test for HIV according to local regulations.
  • Hepatitis B (HBV) or hepatitis C (HCV). All patients must be screened for HBV and HCV up to 28 days prior to study drug start. Patients positive for HBsAg or HBcAb will be eligible if they are negative for HBV-DNA, these patients should receive prophylactic antiviral therapy. Patients positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA.
  • CMV PCR positive at baseline
  • Major surgery within 4 weeks of first dose of study drug
  • Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety at undue risk
  • Uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization
  • Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel currently affecting absorption, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction
  • History of or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
  • Concurrent diagnosis of pheochromocytoma
  • Lactating or pregnant. Women of child bearing potential must have a pregnancy test prior performed a maximum of 7 days before the start of treatment, and a negative result must be documented
  • Patients receiving any other anti-cancer study agents
  • Known lymphomatous involvement of the central nervous system
  • Seizure disorder requiring medication
  • Patients who require warfarin or other vitamin K antagonists for anticoagulation (other anticoagulants are allowed after consultation with the overall study chair).
  • Concurrent administration of medications or foods that are strong inhibitors or inducers of CYP3A, CYP3A substrates with NTI, and P-gp inhibitors taken within 7 days of starting study treatment.
  • Herbal medications excluded within 7 days of starting study treatment
  • Uncontrolled arterial hypertension despite optimal medical management
  • Type 1 or type 2 diabetes mellitus with a HbA1c > 8.5%
  • Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation

Trial locations and contacts

3 sites in 1 country.

United States3 sites

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215

  • City of Hope Cancer Center

    Duarte, California, 91010

  • Siteman Cancer Center at Washington University

    St Louis, Missouri, 63110

Other trials in United States

About this study

Official title: A Phase I/II Study of Copanlisib Plus Venetoclax for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

This research study is evaluating the combination of two drugs, copanlisib and venetoclax, as a possible treatment for trelapsed/refractory diffuse large B-cell lymphoma (DLBCL)

The names of the study drugs involved in this study are:

  • Copanlisib
  • Venetoclax
Read the detailed description

This study is an open-label, multi-center, non-randomized phase I/II study of the combination treatment copanlisib + venetoclax in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Phase I clinical trials test the safety of investigational drugs, and also try to define the appropriate dose of the investigational drugs to use for further studies. Phase II clinical trials test the safety and effectiveness of investigational drugs to learn whether the drugs work in treating a specific disease."Investigational" means that the drugs are being studied.

Copanlisib is an IV medication that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior therapies. Venetoclax is an oral medication that is approved by the U.S. FDA for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and certain patients with acute myeloid leukemia (AML). The FDA has not approved copablisib or venetoclax for the treatment of DLBCL or the combination of copanlisib and venetoclax as a treatment for any disease.

In the phase I portion of this study, the investigators are looking to determine the dose of venetoclax that is safe to give with copanlisib and to see what the side effects are of this combination.

In the phase II trial, the investigators will be determining how effective venetoclax and copanlisib are for the treatment of R/R DLBCL. Data from laboratory suggest that some subsets of DLBCL are enriched for mutations that make them sensitive to the combination of copanlisib plus venetoclax. This study will look at genetic changes in your cancer and determine if abnormalities in specific genes make these drugs more or less effective.

It is expected that about 48 people will take part in this research study.

Bayer, a pharmaceutical company, is supporting this research study by providing the study drug copanlisib and funding for this study. Abbvie, a pharmaceutical company, is supporting this research study by providing the study drug venetoclax and funding for this study.

Being tested
Copanlisib, Venetoclax
Keywords
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Medical subject headings
Lymphoma, Large B-Cell, Diffuse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CopanlisibDrug

    Also called Aliqopa

    Intravenous infusion

  • VenetoclaxDrug

    Also called Venclexta

    Tablet taken orally

Study groups in NCT04572763
Study groupRoleWhat they receive
Dose Escalation Copanlisib + VenetoclaxExperimentalPhase 1 * Dose escalation will occur using a 3+3 design * Copanlisib will be administered IV on days 1, 8 and 15 in 28 day cycle * Venetoclax will be administered orally daily for each 28-day cycle. During cycle 1, a venetoclax dose ramp-up is performed in the outpatient setting
Receives: Drug: Copanlisib; Drug: Venetoclax
Recommended phase II dose (RP2D) Copanlisib + VenetoclaxExperimentalPatients will be treated with copanlisib in combination with venetoclax, administered at the Recommended phase II dose (RP2D).
Receives: Drug: Copanlisib; Drug: Venetoclax

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum tolerated dose of venetoclax in combination with copanlisib (recommended phase II dose (RP2D) - Phase 1

    The highest dose of the drug combination that does not cause unacceptable side effects as assessed by protocol-specified DLT criteria.

    Measured: 28 Days up to 1 year

  2. Overall response rate (ORR) - Phase II

    Defined as the partial response (PR) and complete response (CR) rate, according to the Lugano criteria.

    Measured: 28 Days

Secondary outcomes (6)

  1. Partial response Rate (PR)

    Per Lugano criteria

    Measured: 28 Days

  2. Complete response Rate (CR)

    Per Lugano criteria

    Measured: 28 Days

  3. Duration of response (DOR)

    Legnth of time the patients respond to therapy

    Measured: Every 3 months to 1 year

  4. Progression-free survival (PFS)

    The time from randomization (or registration) to progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation.

    Measured: Time from randomization (or registration) to the date of first documented progression or date of death from any cause, whichever comes first, for up to 5 years.

  5. Overall survival (OS)

    The time from randomization (or registration) to death due to any cause or censored at date last known alive.

    Measured: Time from randomization (or registration) to the date of death from any cause, assessed for up to 5 years.

  6. Exome sequencing

    A genomic classifier will be applied to whole exome sequencing (WES) of DLBCL biopsy samples to determine genomic cluster.

    Measured: Up to 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Oct 2020
  2. Study start8 Sep 2021
  3. Primary completion29 Jul 2025
  4. Study completion29 Jul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
48 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04572763
Sponsor's protocol ID
20-069
Status last verified
Jan 2026
First submitted
22 Sep 2020
Last updated
7 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Copanlisib and Venetoclax in people with Diffuse Large B Cell Lymphoma and Relapsed Diffuse Large B-Cell Lymphoma, run by Dana-Farber Cancer Institute at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum tolerated dose of venetoclax in combination with copanlisib (recommended phase II dose (RP2D) - Phase 1 (time frame: 28 Days up to 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04572763.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in